SCHEMBL5855798

SCHEMBL5855798

COC(=O)C(C)(C)OCCCCCCC(NC(=O)c1ccc(C(C)(C)C)cc1)C(C)=O

nearest known ligand 0.39

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
MAPT P10636 3/20 0.38
ALDH1A1 P00352 3/20 0.38
RAB9A P51151 3/20 0.38
MEN1 O00255 2/20 0.38
KMT2A Q03164 2/20 0.38
SMN1; SMN2 Q16637 2/20 0.38
HTT P42858 2/20 0.38
NR1H4 Q96RI1 3/20 0.38
PRSS1 P07477 2/20 0.37
CTSG P08311 2/20 0.37
CTRB1 P17538 2/20 0.37
CMA1 P23946 2/20 0.37
LMNA P02545 3/20 0.37
ALOX15 P16050 1/20 0.37
APEX1 P27695 1/20 0.37
MAPK1 P28482 1/20 0.37
RECQL P46063 1/20 0.37
HSD17B10 Q99714 1/20 0.37
TDP1 Q9NUW8 1/20 0.37
HDAC1 Q13547 3/20 0.37

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL5856228 0.91 TDP1 (0.38) MAPTALDH1A1RAB9AMEN1KMT2A
SCHEMBL5856188 0.90 POLB (0.44) MEN1KMT2AHTTPRSS1CTSG
SCHEMBL5855896 0.90 CTSL (0.41) ALDH1A1KMT2APRSS1CTSGCTRB1
SCHEMBL5855147 0.90 NR1H4 (0.41) MAPTALDH1A1RAB9AMEN1KMT2A
SCHEMBL5855731 0.90 PRSS1 (0.47) PRSS1CTSGCTRB1CMA1HDAC1
SCHEMBL5855758 0.90 PRSS1 (0.47) PRSS1CTSGCTRB1CMA1HDAC1
SCHEMBL5855987 0.90 PRSS1 (0.47) PRSS1CTSGCTRB1CMA1HDAC1
SCHEMBL5857524 0.83 CYP4F2 (0.43) MAPTMEN1KMT2ASMN1; SMN2PRSS1
SCHEMBL5858508 0.82 TGM2 (0.45) RAB9ANR1H4NPC1POLBCASP3
SCHEMBL5857551 0.81 PPARG (0.40) MAPTMEN1KMT2ASMN1; SMN2PRSS1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 10 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-7144906-B2 Heterocyclic compounds NIPPON SHINYAKU CO., LTD. (JP) 2006-12-05 US disclosed
US-7030143-B2 Heterocyclic compounds NIPPON SHINYAKU CO., LTD. (JP) 2006-04-18 US disclosed
US-7022723-B2 Heterocyclic compounds NIPPON SHINYAKU CO., LTD. (JP) 2006-04-04 US disclosed
EP-1634876-A2 Heterocyclic compounds for the treatment of hyperlipidemia agents Nippon Shinyaku Co., Ltd. (JP) 2006-03-15 EP disclosed
US-6998412-B2 Heterocyclic compounds NIPPON SHINYAKU CO., LTD. (JP) 2006-02-14 US disclosed
US-20050009892-A1 Heterocyclic compounds NIPPON SHINYAKU CO., LTD. (JP) 2005-01-13 US disclosed
US-20050009785-A1 Heterocyclic compounds KUWABARA KENJI (JP) 2005-01-13 US disclosed
US-20040162325-A1 Heterocyclic compounds KUWABARA KENJI (JP) 2004-08-19 US disclosed
US-20030166697-A1 Heterocyclic compounds NIPPON SHINYAKU CO., LTD. (JP) 2003-09-04 US disclosed
EP-1295875-A1 HETEROCYCLIC COMPOUNDS Nippon Shinyaku Co., Ltd. (JP) 2003-03-26 EP disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20050009785-A1 Heterocyclic compounds LIPC, GPR119, APOB MAPT 4793/4885ALDH1A1 760/4885RAB9A 3996/4885
US-20050009892-A1 Heterocyclic compounds GPR119, LIPC, LIPE MAPT 4799/4885ALDH1A1 571/4885RAB9A 3631/4885
US-20040162325-A1 Heterocyclic compounds LIPE, GPR119, LIPC MAPT 4835/4885ALDH1A1 557/4885RAB9A 3492/4885
US-20030166697-A1 Heterocyclic compounds LIPE, GPR119, LIPC MAPT 4835/4885ALDH1A1 557/4885RAB9A 3492/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.